| Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma RJ Motzer, TE Hutson, MR Olsen, GR Hudes, JM Burke, WJ Edenfield, ... Journal of clinical oncology 30 (12), 1371-1377, 2012 | 306 | 2012 |
| Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang, J Shen, HE Vezina, ... Annals of Oncology 28 (8), 2002-2008, 2017 | 208 | 2017 |
| Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer GV Long, SS Tykodi, JG Schneider, C Garbe, G Gravis, M Rashford, ... Annals of Oncology 29 (11), 2208-2213, 2018 | 194 | 2018 |
| Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug M Morgen, C Bloom, R Beyerinck, A Bello, W Song, K Wilkinson, ... Pharmaceutical research 29, 427-440, 2012 | 162 | 2012 |
| Clinical pharmacology considerations for the development of immune checkpoint inhibitors J Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M Gupta The Journal of Clinical Pharmacology 57, S26-S42, 2017 | 126 | 2017 |
| Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma CH Barrios, D Hernandez‐Barajas, MP Brown, SH Lee, L Fein, JH Liu, ... Cancer 118 (5), 1252-1259, 2012 | 102 | 2012 |
| Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer Y Feng, X Wang, G Bajaj, S Agrawal, A Bello, B Lestini, FG Finckenstein, ... Clinical Cancer Research 23 (18), 5394-5405, 2017 | 99 | 2017 |
| Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects DA Gajjar, A Bello, Z Ge, L Christopher, DM Grasela Antimicrobial agents and chemotherapy 47 (7), 2256-2263, 2003 | 84 | 2003 |
| Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies L Liu, A Bello, MJ Dresser, D Heald, SF Komjathy, E O'Mara, M Rogge, ... The Journal of Clinical Pharmacology 56 (2), 143-151, 2016 | 79 | 2016 |
| Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections S Van Wart, L Phillips, EA Ludwig, R Russo, DA Gajjar, A Bello, ... Antimicrobial agents and chemotherapy 48 (12), 4766-4777, 2004 | 70 | 2004 |
| Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types X Zhao, J Shen, V Ivaturi, M Gopalakrishnan, Y Feng, BJ Schmidt, ... Annals of Oncology 31 (2), 302-309, 2020 | 65 | 2020 |
| Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects TR Johnson, W Tan, L Goulet, EB Smith, S Yamazaki, GS Walker, ... Xenobiotica 45 (1), 45-59, 2015 | 58 | 2015 |
| A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors CJ Sweeney, EG Chiorean, CF Verschraegen, FC Lee, S Jones, M Royce, ... Journal of clinical oncology 28 (29), 4513-4520, 2010 | 56 | 2010 |
| Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. C Li, C Alvey, A Bello, KD Wilner, W Tan Journal of Clinical Oncology 29 (15_suppl), e13065-e13065, 2011 | 51 | 2011 |
| Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects H Xu, M O'Gorman, T Boutros, N Brega, C Kantaridis, W Tan, A Bello The Journal of Clinical Pharmacology 55 (1), 104-113, 2015 | 49 | 2015 |
| Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma L Gibiansky, C Passey, A Roy, A Bello, M Gupta Journal of pharmacokinetics and pharmacodynamics 43, 243-257, 2016 | 37 | 2016 |
| Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects J Andrews, D Honeybourne, G Jevons, M Boyce, R Wise, A Bello, ... Journal of Antimicrobial Chemotherapy 51 (3), 727-730, 2003 | 37 | 2003 |
| Effects of the des-F (6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats EM Kappel, M Shakibaei, A Bello, R Stahlmann Antimicrobial agents and chemotherapy 46 (10), 3320-3322, 2002 | 37 | 2002 |
| The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects H Xu, M O’Gorman, W Tan, N Brega, A Bello European journal of clinical pharmacology 71, 1441-1449, 2015 | 35 | 2015 |
| Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants V Perera, G Abelian, D Li, Z Wang, L Zhang, S Lubin, W Chen, A Bello, ... Clinical Pharmacokinetics 61 (6), 857-867, 2022 | 31 | 2022 |
